Elan said this evening that a mid-stage trial of the company's vaccine to treat Alzheimer's disease has resumed following a six-week suspension prompted by safety concerns.
'Last week dosing was restarted,' Elan's CEO Kelly Martin told analysts and money managers at the Goldman Sachs annual Global Healthcare Conference in California today.
He said the study, which had been suspended in mid-April, was 'back on track'.
The suspension was meant to allow Elan and partner Wyeth to examine a potentially serious side effect suffered by one patient in the mid-stage trial.
The patient was hospitalised with skin lesions that a lead researcher suspected was a case of vasculitis, an inflammation of blood vessels.
Elan and Wyeth are also co-developing another Alzheimer's drug, called AAB-001, that is farther along in testing and is considered by many analysts to be the most promising product in development against the degenerative brain disease. The compound recently began late-stage trials.
